AstraZeneca PLC Fights With Pediatrician Group Over Preemie Drug Guidelines

Once again, there is controversy over an expensive drug for premature babies.

At issue are new American Academy of Pediatrics guidelines that recommend scaling back usage of a drug called Synagis, which costs several thousand dollars and is sold by AstraZeneca 'sAZN.LN -0.23% MedImmune unit, because evidence shows the medicine benefits few children other than the youngest premature infants.

Help employers find you! Check out all the jobs and post your resume.